ElectroCore

electroCore Announces the Launch of Truvaga Plus® for General Wellness

Retrieved on: 
Monday, April 8, 2024
E-commerce, ElectroCore

ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024.

Key Points: 
  • ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024.
  • Our first general wellness product, Truvaga 350, exceeded our expectations and Truvaga Plus will be an exciting addition to the Truvaga brand.
  • Truvaga Plus is engineered to seamlessly integrate into daily routines and is a holistic and convenient solution to manage stress and enhance overall wellbeing.
  • “I am thrilled to announce the launch of our next generation, app-enabled general wellness product, Truvaga Plus,” stated Dan Goldberger, CEO of electroCore.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, April 2, 2024
Vagus nerve, Central nervous system, Fibromyalgia, Patent, TBI, Anxiety, Software, United States patent law, ElectroCore, PTSD, Medical device

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
  • The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
    US Patent No.
  • The therapy regimen comprises generating an electrical signal for approximately 5 minutes to 30 minutes.
  • The electrical impulses are bursts of 2 to 20 sinusoidal pulses.

electroCore to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, March 12, 2024
Conference, ElectroCore

Please contact Roth MKM to schedule a 1x1 meeting.

Key Points: 
  • Please contact Roth MKM to schedule a 1x1 meeting.
  • In addition, Dan Goldberger, CEO of electroCore, Inc. is scheduled to participate in the 23rd Annual Needham Virtual Healthcare Conference on April 8 – 11, 2024.
  • Mr. Goldberger will give a company presentation on April 8th at 3:00 pm and will host 1x1 investor meetings throughout the conference.
  • Please contact Needham to schedule a 1x1 meeting.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, February 6, 2024
C-reactive protein, Patent, Virus, COVID, Disorder, Vagus nerve, Patient, Blood, United States patent law, Coronaviridae, ElectroCore

ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).

Key Points: 
  • ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).
  • U.S. Patent No.
  • 11,894,148 entitled “Systems and Methods for Treating Patients With Diseases Associated With Viruses” generally relates to methods for treating disorders with viruses in the COVID family using electrical impulses transcutaneously to the vagus nerve for about 30 seconds to about 5 minutes, from 2 to 5 times per day, to reduce a level of C-reactive protein in the blood of the patient.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, January 9, 2024
United States patent law, Post-traumatic stress disorder, Patent, ElectroCore, Vagus nerve, PTSD, Meat

ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).

Key Points: 
  • ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).
  • U.S. Patent No.
  • 11,865,329 entitled “Vagal Nerve Stimulation for Treating Post-Traumatic Stress Disorder” generally relates to methods for treating the symptoms of post-traumatic stress disorder (PTSD) that include applying one or more electrical impulses transcutaneously to the vagus nerve for approximately 90 seconds to approximately 3 minutes.
  • The electrical impulses may comprise bursts of 2 to 20 pulses.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, December 26, 2023
Patent, HRV, ElectroCore, United States patent law, Medical imaging

ROCKAWAY, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • ROCKAWAY, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
  • The two patents were issued on December 26, 2023, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
    US Patent No.
  • 11,850,056 entitled “Devices and Methods for Remote Therapy and Patient Monitoring” generally relates to systems and methods for treating medical conditions that include delivering an nVNS therapy regimen, detecting a heart rate variability (HRV) of the patient, and comparing the HRV with data related to parameters of the therapy regimen.
  • US Patent No.

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

Retrieved on: 
Tuesday, December 12, 2023
Intellectual property, ElectroCore, App Store (iOS/iPadOS), Patent, Neurostimulation, Disease, Head, Headache, Disorder, United States patent law, Neck

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or neck of a patient for treatment of various disorders, such as primary headache.

Key Points: 
  • ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or neck of a patient for treatment of various disorders, such as primary headache.
  • U.S. Patent No.
  • “We continue to grow our intellectual property portfolio,” stated Joshua Lev, Chief Strategy Officer of electroCore.
  • “This new patent strengthens our position around systems that utilize mobile applications to control stimulators that treat various disorders such as primary headache, which may be useful as we develop our next generation application enabled products and devices.”

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

Retrieved on: 
Wednesday, November 15, 2023
Kanimozhi NVN Somu, ElectroCore, ECOR, Oil, Cassette tape

Analyst Day: “Accessing the Power of Vagus Nerve Stimulation with gammaCore™”Date: Tuesday, November 21, 2023Time: 1:30pm – 2:30pm ESTRegistration: https://electrocore.zoom.us/webinar/register/WN_wcHtB4caT--D58SYPiyryw

Key Points: 
  • ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “Accessing the Power of Vagus Nerve Stimulation with gammaCore™” on November 21, 2023 at 1:30pm EST.
  • The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology platform that is embodied in its gammaCore product.
  • Participants interested in listening to the webinar can register by clicking here .
  • Following the live presentation, a playback of the webinar will be available on the “Investors” section of the company’s website at: www.electrocore.com.

electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

Retrieved on: 
Tuesday, November 7, 2023
ECOR, Canaccord Genuity, ElectroCore, Diagnosis, Digital health, Westin Hotels & Resorts, Mobile phone, Cryptocurrency, Pharmaceutical industry

ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023.

Key Points: 
  • ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023.
    electroCore will host 1x1 investor meetings on November 16, 2023.
  • Please contact your Canaccord representative to schedule a 1x1 meeting.

Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023
Name, Abdominal pain, Constipation, American College, Vomiting, Gastroenterology, ElectroCore, MD, Kanimozhi NVN Somu, Research, GLS, Nausea, VUE, Quality of life, Disorder, FD, Symantec Endpoint Protection, ECOR, Plague, Woman, Depression, Indigestion, Pharmaceutical industry, Medical device, Birth control, Patient, Gastroparesis

The primary endpoint was reducing the use of antinausea medications by using nVNS as the primary rescue treatment for nausea exacerbations.

Key Points: 
  • The primary endpoint was reducing the use of antinausea medications by using nVNS as the primary rescue treatment for nausea exacerbations.
  • The study showed nVNS reduced the use of rescue pills per day by more than 50% (p=0.0007; Figure 1).
  • This benefit was maintained throughout each 4-week treatment period of the crossover study as well as during the two, two-week, washout periods.
  • Overall significance (Type 3 F test): p=0.0007
    Presentation 68: Non-Invasive Vagal Nerve Stimulation Reduces Nausea Rescue Medication in Patients With Gastroparesis and Related Disorders, With Additional Benefits on Multiple Other Associated Symptom